和铂医药-B(02142)：根据与Spruce订立的授权及合作协议行使认股权证

Core Viewpoint - HBM Alpha Therapeutics (HBMAT), a biotech company incubated by the company, has entered into a licensing and collaboration agreement with Spruce Biosciences Inc. to advance novel corticotropin-releasing hormone (CRH) targeted therapies for various diseases [1] Group 1 - The agreement allows HBMAT and its affiliates to acquire warrants related to a minority equity stake to purchase common shares of Spruce [1] - The company and HBMAT plan to exercise the warrants on January 19, 2026, which will result in the company holding approximately 3.8% of Spruce's outstanding shares and about 3.1% of Spruce's fully diluted shares [1]